









Markets
/
Stocks
/
nasdaq-entx
/

Entera Bio Ltd

ENTX

3.110USD

+0.070+2.30%

Close 11/06, 16:00（ET）Quotes delayed by 15 min

141.36MMarket Cap

LossP/E TTM



Entera Bio Ltd

3.110

+0.070+2.30%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Entera Bio Ltd

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Entera Bio Ltd's Score

Industry at a Glance

Industry Ranking

100 / 407

Overall Ranking

216 / 4615

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

10.000

Target Price

+228.95%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Entera Bio Ltd Highlights

StrengthsRisks

Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 35.07% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 181.00K.

Undervalued

The company’s latest PE is -12.13, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 10.07M shares, decreasing 2.21% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 64.30K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.48.

Financial Health

Currency: USD Updated: 2025-11-06

The company's current financial score is 6.54, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 23.82%.

Score

Industry at a Glance

Previous score

6.54

Change



Financials

9.30

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.94

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.13

Key Metrics

Free cash flow

No Data

Entera Bio Ltd's Company Valuation

Currency: USD Updated: 2025-11-06

The company’s current valuation score is 6.37, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -12.13, which is -86.83% below the recent high of -1.60 and 0.00% above the recent low of -12.13.

Score

Industry at a Glance

Previous score

6.37

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 100/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-06

The company’s current earnings forecast score is 8.00, which is equal to the Biotechnology & Medical Research industry's average of 8.00. The average price target for Entera Bio Ltd is 10.00, with a high of 10.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

10.000

Target Price

+228.95%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Entera Bio Ltd

ENTX

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-06

The company’s current price momentum score is 9.41, which is higher than the Biotechnology & Medical Research industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 3.51 and the support level at 2.41, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.43

Change

-0.02

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.105

Buy

RSI(14)

72.204

Buy

STOCH(KDJ)(9,3,3)

88.918

Overbought

ATR(14)

0.233

High Vlolatility

CCI(14)

136.945

Buy

Williams %R

10.000

Overbought

TRIX(12,20)

1.371

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

2.940

Buy

MA10

2.732

Buy

MA20

2.582

Buy

MA50

2.182

Buy

MA100

2.060

Buy

MA200

2.048

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-06

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Knoll Capital Management, LLC

5.88M

OPKO Health Inc

3.87M

+4.88%

D.N.A Biomedical Solutions, Ltd.

3.73M

Point72 Asset Management, L.P.

Star Investors

2.70M

Centillion Fund Inc

2.40M

Schonfeld Strategic Advisors LLC

604.52K

+0.90%

Parkman Healthcare Partners LLC

355.82K

-19.06%

Lieberman (Gerald M)

324.96K

Toledano (Miranda Jayne)

291.45K

+163.16%

Northern Trust Global Investments Limited

200.75K

+0.96%

Risk Assessment

Currency: USD Updated: 2025-11-06

The company’s current risk assessment score is 2.71, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.69. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.